EP2535337

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    18.7.2006
  • :
    23.8.2017
  • :
    12160493.8
  • :
    17.7.2026
  • :
    Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form

18.7.2006
23.8.2017
  • :
    Novartis AG
  • :
    Lichtstrasse 35, 4056, Basel, CH
  • :
    Novartis Pharma GmbH
  • :
    Brunner Strasse 59, 1230, Wien, AT
  • :
    Manley, Paul W.
  • :
    Arlesheim, CH
  • :
    Shieh, Wen-Chung
  • :
    Berkeley Heights, NJ, US
  • :
    Sutton, Paul Allen
  • :
    Parsippany, NJ, US
  • :
    Karpinski, Piotr H.
  • :
    Lincoln Park, NJ, US
  • :
    Wu, Raeann
  • :
    Pine Brook, NJ, US
  • :
    Monnier, Stéphanie
  • :
    Raedersheim, FR
  • :
    Brozio, Jörg
  • :
    Basel, CH
  • :
    701405 P
  • :
    20.7.2005
  • :
    US
  • :
    716214 P
  • :
    12.9.2005
  • :
    US
  • :
    C07D 401/14, A61K 31/506, A61P 35/00